Table 2 Subgroup analysis of efficacy and safety outcome of galcanezumab for the treatment of migraine
Efficacy | Safety | |||||
|---|---|---|---|---|---|---|
50% ≥ response | MHD | TEAE | ||||
RR (95% CI) | P value | WMD (95% CI) | P value | RR (95% CI) | P value | |
1. 120 mg Galcanezumab | ||||||
3 months | 1.469 (1.166, 1.850) | 0.006 | −2.090 (−3.237, − 0.943) | 0.000 | 1.144 (1.003, 1.304) | 0.045 |
6 months | 1.513 (1.286, 1.779) | 0.013 | −1.774 (−2.256, − 1.291) | 0.000 | 1.033 (0.950, 1.123) | 0.443 |
2. 240 mg Galcanezumab | ||||||
3 months | 1.589 (1.270, 1.987) | 0.013 | −1.880 (−2.983, −0.777) | 0.001 | 1.155 (1.014, 1.316) | 0.030 |
6 months | 1.582 (1.406, 1.780) | 0.000 | −1.839 (−2.324, − 1.354) | 0.000 | 1.170 (1.082, 1.266) | 0.000 |
3. 300 mg Galcanezumab | ||||||
1 month | N/A | N/A | N/A | N/A | 1.286 (0.788, 2.097) | 0.314 |
3 months | 1.509 (1.166, 1.954) | 0.000 | −1.200 (−2.012, −0.388) | 0.004 | 1.087 (0.927, 1.275) | 0.302 |
6 months | 1.147 (0.928, 1.418) | 0.000 | −0.620 (−1.565, 0.325) | 0.198 | 0.935 (0.693, 1.261) | 0.659 |